SkinBioTherapeutics PLC Result of Placing (7583T)
November 17 2023 - 2:00AM
UK Regulatory
TIDMSBTX
RNS Number : 7583T
SkinBioTherapeutics PLC
17 November 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED
STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR
ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO
ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR
BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK
LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK
MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE
TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED IN THIS
ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF
SUCH INSIDE INFORMATION, AS PERMITTED BY UK MAR. UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL
THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.
17 November 2023
SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Company")
Result of Placing
SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life
sciences company focused on skin health, is pleased to announce
that, further to the announcement made on 16 November 2023
regarding the Placing (the "Launch Announcement"), it has raised
GBP3.0 million (before expenses) via the placing of 15,908,298
Placing Shares at the Issue Price of 19 pence per share. The
Placing was undertaken through an accelerated bookbuild and was
materially oversubscribed.
The Placing Shares will, when issued, represent, in aggregate,
circa 9.2 per cent. of the Company's issued ordinary share capital
immediately prior to the Placing.
The Placing Price of 19 pence per Placing Share represents a 9.5
per cent. discount to the closing middle market price of 21 pence
per Ordinary Share on 15 November 2023, being the last practicable
dealing date prior to the publication of the Launch
Announcement.
A further announcement will be made on 21 November 2023
announcing the result of the Retail Offer.
Application for Admission to Trading
The Placing Shares, when issued, will be fully paid and will
rank pari passu in all respects with the Existing Ordinary Shares,
including the right to receive all dividends and other
distributions declared, made or paid after the date of issue.
Application has been made for the Placing Shares to be admitted
to trading on AIM ("Admission"). It is expected that Admission will
take place on or before 8.00 a.m. on 22 November 2023 and that
dealings in the Placing Shares on AIM will commence at the same
time.
The Placing is conditional upon, among other things, the Placing
Agreement not being terminated in accordance with its terms and
Admission becoming effective.
Capitalised terms used in this announcement (this
"Announcement") have the meanings given to them in the Launch
Announcement, unless the context provides otherwise.
For further information
SkinBioTherapeutics plc Tel: +44 (0) 191
Stuart J . Ashman, CEO 495 7325
Manprit Randhawa, CFO
Cavendish Securities plc (Nominated Adviser Tel: +44 (0) 20
& Broker) 7397 8900
Giles Balleny, Dan Hodkinson (Corporate
Finance)
Charlie Combe (Corporate Broking)
Dale Bellis, Tamar Cranford-Smith (Sales)
Instinctif Partners (financial press) Tel: +44 (0) 20
Melanie Toyne-Sewell / Tim Field 7457 2020
SkinBio@instinctif.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROIDBBDBXDBDGXL
(END) Dow Jones Newswires
November 17, 2023 02:00 ET (07:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024